NO20012534L - Use of parvoviral capsid particles in the inhibition of cell proliferation and migration - Google Patents
Use of parvoviral capsid particles in the inhibition of cell proliferation and migrationInfo
- Publication number
- NO20012534L NO20012534L NO20012534A NO20012534A NO20012534L NO 20012534 L NO20012534 L NO 20012534L NO 20012534 A NO20012534 A NO 20012534A NO 20012534 A NO20012534 A NO 20012534A NO 20012534 L NO20012534 L NO 20012534L
- Authority
- NO
- Norway
- Prior art keywords
- cells
- migration
- parvoviral capsid
- inhibition
- cell proliferation
- Prior art date
Links
- 210000000234 capsid Anatomy 0.000 title abstract 2
- 238000013508 migration Methods 0.000 title abstract 2
- 239000002245 particle Substances 0.000 title abstract 2
- 230000013152 negative regulation of cell migration Effects 0.000 title 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 230000010261 cell growth Effects 0.000 abstract 2
- 210000002889 endothelial cell Anatomy 0.000 abstract 2
- 108090000565 Capsid Proteins Proteins 0.000 abstract 1
- 102100023321 Ceruloplasmin Human genes 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 208000017733 acquired polycythemia vera Diseases 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000012010 growth Effects 0.000 abstract 1
- 230000003394 haemopoietic effect Effects 0.000 abstract 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract 1
- 238000002513 implantation Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000005012 migration Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000037244 polycythemia vera Diseases 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 238000011476 stem cell transplantation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Surgery (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Oppfinnelsen beskrevet heri vedrører oppdagelsen av fremgangsmåter og sammen- setninger for å inhibere vekst og/eller migrering av celler som har P-antigenet, som inkluderer, men ikke er begrenset til, celler av hematopoetisk opprinnelse og endotel- celler. Mer spesifikt blir parvoviruskapsidpartikler eller fragmenter av parvovirus- kapsidproteiner brukt for å fremstille medikamenter som kan administreres til et individ for å inhibere hematopdéTisk forløpercellevekst (f.eks. forut for stamcelletransplanta- sjon), endotelcellevekst (f.eks. som en anti-tumorgenesebehandling eller for å hindre restenose eller fibrotisk oppbygging etter proteseimplantasjon) eller for å hindre sykdommer som involverer unormal proliferering av celler som har P-antigenet (f.eks. polycytemi vera).The invention described herein relates to the discovery of methods and compositions for inhibiting the growth and / or migration of cells having the P antigen, which includes, but is not limited to, cells of hematopoietic origin and endothelial cells. More specifically, parvoviral capsid particles or fragments of parvoviral capsid proteins are used to prepare drugs that can be administered to an individual to inhibit hematopoietic progenitor cell growth (e.g., prior to stem cell transplantation), endothelial cell growth (e.g., as an anti-tumor gene, or to prevent restenosis or fibrotic buildup after prosthetic implantation) or to prevent diseases involving abnormal proliferation of cells that have the P antigen (e.g., polycythemia vera).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9804022A SE520177C2 (en) | 1998-11-24 | 1998-11-24 | Use of empty, non-infectious, recombinant parvoviral capsid particles, or β-antigen-blocking portions thereof, for the manufacture of drugs for inhibiting hematopoietic stem cells |
| PCT/IB1999/002112 WO2000030668A2 (en) | 1998-11-24 | 1999-11-23 | Use of parvovirus capsid particles in the inhibition of cell proliferation and migration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20012534D0 NO20012534D0 (en) | 2001-05-23 |
| NO20012534L true NO20012534L (en) | 2001-06-29 |
Family
ID=20413393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20012534A NO20012534L (en) | 1998-11-24 | 2001-05-23 | Use of parvoviral capsid particles in the inhibition of cell proliferation and migration |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1131085A2 (en) |
| JP (1) | JP2003516927A (en) |
| KR (1) | KR20010080518A (en) |
| CN (1) | CN1328469A (en) |
| AU (1) | AU2566600A (en) |
| CA (1) | CA2352043A1 (en) |
| CZ (1) | CZ20011369A3 (en) |
| HU (1) | HUP0104298A2 (en) |
| IS (1) | IS5931A (en) |
| MX (1) | MXPA01004949A (en) |
| NO (1) | NO20012534L (en) |
| PL (1) | PL348640A1 (en) |
| SE (1) | SE520177C2 (en) |
| WO (1) | WO2000030668A2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1275658B1 (en) * | 2001-07-10 | 2006-11-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Compositions comprising a parvovirus VP1-variant and a parvovirus NS1 protein for induction of cytolysis |
| EP1791858B1 (en) * | 2004-09-24 | 2010-04-21 | Intercell AG | Modified vp1-capsid protein of parvovirus b19 |
| CN101475942B (en) * | 2008-11-28 | 2012-05-23 | 中国人民解放军第四军医大学 | B19 virus VP1 unique region gene |
| US9598468B2 (en) | 2011-05-18 | 2017-03-21 | University Of Florida Research Foundation, Incorporated | Polypeptides and vectors for targeting HER2/neu expressing cells and uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL92298A (en) * | 1988-11-14 | 2001-04-30 | Us Secretary U S Dept Of Comme | Method for producing isolated empty b19 parvovirus capsids, introducing genes into cells utilizing the same, diagnostic assays for detecting parvovirus infection and an anti-parvovirus vaccine containing said capsids |
| NL8902301A (en) * | 1989-09-14 | 1991-04-02 | Rijksuniversiteit | HUMAN PARVOVIRUS B19 PROTEINS, THEIR PRODUCTION AND THEIR USE IN DIAGNOSTIC ASSAYS AND VACCINES. |
-
1998
- 1998-11-24 SE SE9804022A patent/SE520177C2/en not_active IP Right Cessation
-
1999
- 1999-11-23 CA CA002352043A patent/CA2352043A1/en not_active Abandoned
- 1999-11-23 HU HU0104298A patent/HUP0104298A2/en unknown
- 1999-11-23 PL PL99348640A patent/PL348640A1/en unknown
- 1999-11-23 JP JP2000583551A patent/JP2003516927A/en active Pending
- 1999-11-23 CZ CZ20011369A patent/CZ20011369A3/en unknown
- 1999-11-23 MX MXPA01004949A patent/MXPA01004949A/en unknown
- 1999-11-23 KR KR1020017006374A patent/KR20010080518A/en not_active Withdrawn
- 1999-11-23 CN CN99813653A patent/CN1328469A/en active Pending
- 1999-11-23 AU AU25666/00A patent/AU2566600A/en not_active Abandoned
- 1999-11-23 EP EP99968407A patent/EP1131085A2/en not_active Withdrawn
- 1999-11-23 WO PCT/IB1999/002112 patent/WO2000030668A2/en not_active Ceased
-
2001
- 2001-05-02 IS IS5931A patent/IS5931A/en unknown
- 2001-05-23 NO NO20012534A patent/NO20012534L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA01004949A (en) | 2003-03-10 |
| CN1328469A (en) | 2001-12-26 |
| SE520177C2 (en) | 2003-06-03 |
| WO2000030668A8 (en) | 2000-09-14 |
| WO2000030668A3 (en) | 2000-11-09 |
| NO20012534D0 (en) | 2001-05-23 |
| WO2000030668A9 (en) | 2001-04-05 |
| CZ20011369A3 (en) | 2001-10-17 |
| IS5931A (en) | 2001-05-02 |
| CA2352043A1 (en) | 2000-06-02 |
| JP2003516927A (en) | 2003-05-20 |
| WO2000030668A2 (en) | 2000-06-02 |
| SE9804022D0 (en) | 1998-11-24 |
| EP1131085A2 (en) | 2001-09-12 |
| AU2566600A (en) | 2000-06-13 |
| HUP0104298A2 (en) | 2002-03-28 |
| KR20010080518A (en) | 2001-08-22 |
| PL348640A1 (en) | 2002-06-03 |
| SE9804022L (en) | 2000-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kang et al. | Replicative senescence of normal human oral keratinocytes is associated with the loss of telomerase activity without shortening of telomeres | |
| Cummins et al. | HAUSP is required for p53 destabilization | |
| Roche et al. | Comparative proteomic analysis of human mesenchymal and embryonic stem cells: towards the definition of a mesenchymal stem cell proteomic signature | |
| US10900018B2 (en) | Means and methods for generation of breast stem cells | |
| Solana et al. | Molecular and cellular basis of immunosenescence | |
| CN102858964A (en) | Polypeptides | |
| Sanford et al. | A quest for the mechanism of “spontaneous” malignant transformation in culture with associated advances in culture technology | |
| Dogra et al. | Generating long‐lived CD8+ T‐cell memory: Insights from epigenetic programs | |
| Stellavato et al. | [Retracted] Novel Hybrid Gels Made of High and Low Molecular Weight Hyaluronic Acid Induce Proliferation and Reduce Inflammation in an Osteoarthritis In Vitro Model Based on Human Synoviocytes and Chondrocytes | |
| Fikry et al. | Bone marrow and adipose‐derived mesenchymal stem cells alleviate methotrexate‐induced pulmonary fibrosis in rat: comparison with dexamethasone | |
| Yang et al. | l‐Glutathione enhances antioxidant capacity of hyaluronic acid and modulates expression of pro‐inflammatory cytokines in human fibroblast‐like synoviocytes | |
| BR112022004562A2 (en) | Universal donor selection method to identify nk cell donors | |
| Ruef et al. | Granulocyte-macrophage colony-stimulating factor-dependent CD11c-positive cells differentiate into active osteoclasts | |
| WO2019210216A3 (en) | Talen-based and crispr/cas-based gene editing for bruton's tyrosine kinase | |
| Zander et al. | Immortalized mouse cell lines that lack a functional Rev3 gene are hypersensitive to UV irradiation and cisplatin treatment | |
| NO20012534L (en) | Use of parvoviral capsid particles in the inhibition of cell proliferation and migration | |
| NO20060019L (en) | Methods and Preparations for Interferon Therapy | |
| Rakonczay Jr et al. | Chronic inflammation in the pancreas and salivary glands-lessons from similarities and differences in pathophysiology and treatment modalities | |
| Koch et al. | Modeling AEC—new approaches to study rare genetic disorders | |
| Zhang et al. | RSK-3 promotes cartilage regeneration via interacting with rpS6 in cartilage stem/progenitor cells | |
| Tang et al. | Gene expression signatures associated with suppression of TRAMP prostate carcinogenesis by a kavalactone‐rich Kava fraction | |
| Li et al. | Signaling on telomerase: a master switch in cell aging and immortalization | |
| Mahiddine et al. | CD99 isoforms regulate CD1a expression in human monocyte‐derived DCs through ATF‐2/CREB‐1 phosphorylation | |
| Parkinson | Telomerase as a novel and potentially selective target for cancer chemotherapy | |
| Yuan et al. | Chondrogenic differentiation and immunological properties of mesenchymal stem cells in collagen type I hydrogel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |